Literature DB >> 30367464

Narrative review of the effects of antidiabetic drugs on albuminuria.

Habib Yaribeygi1, Stephen L Atkin2, Niki Katsiki3, Amirhossein Sahebkar4,5,6.   

Abstract

Diabetes mellitus is the most prevalent metabolic disorder worldwide. Glycemic control is the main focus of antidiabetic therapy. However, there are data suggesting that some antidiabetic drugs may have intrinsic beneficial renal effects and protect against the development and progression of albuminuria, thus minimizing the risk of diabetic nephropathy. These pharmacological agents can suppress upstream molecular pathways involved in the pathophysiology of diabetes-induced renal dysfunction such as oxidative stress, inflammatory responses, and apoptosis. In this narrative review, the pathophysiology of albuminuria in patients with diabetic nephropathy is discussed. Furthermore, the renoprotective effects of antidiabetic drugs, focusing on albuminuria, are reviewed.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  antidiabetic agents; diabetes mellitus; diabetic nephropathy; oxidative stress; renal dysfunction

Mesh:

Substances:

Year:  2018        PMID: 30367464     DOI: 10.1002/jcp.27503

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Boosting GLP-1 by Natural Products.

Authors:  Habib Yaribeygi; Tannaz Jamialahmadi; Seyed Adel Moallem; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Significance of Metformin Use in Diabetic Kidney Disease.

Authors:  Daiji Kawanami; Yuichi Takashi; Makito Tanabe
Journal:  Int J Mol Sci       Date:  2020-06-14       Impact factor: 5.923

Review 3.  Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.

Authors:  Vjera Ninčević; Tea Omanović Kolarić; Hrvoje Roguljić; Tomislav Kizivat; Martina Smolić; Ines Bilić Ćurčić
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.